Observational studyNeurourology and urodynamics2020
Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study.
Observational study in Neurourology and urodynamics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial.Neurourology and urodynamics · 2026Trial
- Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial.The Journal of urology · 2024Trial
- Management of Persistent Storage Symptoms and Overactive Bladder in Men Diagnosed with Benign Prostatic Hyperplasia: A Narrative Review.Advances in therapy · 2026Review
- Outcomes following intradetrusor onabotulinumtoxinA injections and sacral neuromodulation in older men.BJUI compass · 2026Article
- Article
- Utilization of More Than One Minimally Invasive Overactive Bladder Therapy Among Older Adults; a National Medicare Study.Neurourology and urodynamics · 2026Article
- Exploring the association between the ZJU index and overactive bladder: a cross-sectional study based on NHANES 2011-2018.Translational andrology and urology · 2025Article
- Financial toxicity in lower urinary tract symptoms amongst men.BMC urology · 2025Article
- Vibegron for overactive bladder in men with benign prostatic hyperplasia/obstruction: insights from the COURAGE trial.Translational andrology and urology · 2025Article
- Pharmacotherapy for BPH-related LUTS: associations between medication patterns, persistence, and treatment failure.World journal of urology · 2025Article
- Association between body roundness index and overactive bladder: results from the NHANES 2005-2018.Lipids in health and disease · 2024Article
- Lower Urinary Tract Symptoms in Depression: A Review.Health psychology research · 2023Article
- Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study.Neurourology and urodynamics · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
aimsTo characterize the epidemiology and treatment patterns of adult men (≥40 years) diagnosed with, or treated for, overactive bladder (OAB) and/or benign prostatic hyperplasia (BPH).
methodsThis retrospective observational study used data extracted from the IBM MarketScan Commercial Claims and Encounters database and the Medicare Supplemental Coordination of Benefits database. Men with BPH and/or OAB were identified and observed to assess treatment and diagnostic patterns.
resultsWithin the entire study sample (N = 462 400), BPH diagnosis (61.5%) and BPH treatment (73.7%) were more common than the corresponding values for OAB (25.8% and 7.0%, respectively). Notably, among diagnosed individuals, the dispensation of a corresponding treatment was more likely in individuals diagnosed with BPH (183 672 out of 284 416 = 64.6%) compared with OAB (16 468 out of 119 236 = 13.8%). Among newly diagnosed and/or treated patients (n = 196 576), only 60.3% received treatment. Among treated patients, most experienced only a single type of treatment (93.4%), 6.6% went on to receive a secondary treatment and 3.5% a tertiary. The most common primary treatment was alpha-blocker monotherapy (76.9%) followed by tadalafil monotherapy (16.4%). Among those untreated at first diagnosis, the median time between diagnosis and treatment initiation was 128 days.
conclusionsDiagnosis and management of OAB among males are challenging given the inherent overlap in symptoms observed with BPH. Unsurprisingly, we found that BPH is diagnosed and treated more frequently than OAB; but the differences between diagnosis and treatment patterns for the two conditions highlight the potential undertreatment of OAB and misdirection of therapy for men with a combination of voiding and storage symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.